相关实验视频
Updated: Jul 4, 2025
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
10.0K
在复发性/阻断性扩散性大B细胞淋巴瘤的标准护理治疗结果:现实世界数据分析
Andrew Ip1, Alex Mutebi2, Tongsheng Wang3
1Hackensack Meridian Health, Hackensack University Medical Center, Hackensack, NJ, USA.
Advances in therapy
|February 1, 2024
概括
用标准疗法治疗的复发性或不耐药的扩散性大B细胞淋巴瘤 (DLBCL) 患者的结果仍然很差,特别是那些难以治疗的疾病患者. 这凸显了迫切需要新和有效的治疗选择.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 复发性或不耐药的扩散性大B细胞淋巴瘤 (R/R DLBCL) 尽管在治疗方面取得了进展,但仍是一个重大的临床挑战.
- 目前的治疗模式通常涉及化疗,抗CD20单克隆抗体 (例如,rituximab,obinutuzumab) 或lenalidomide,单独或组合.
研究的目的:
- 在接受常见治疗方案的R/R DLBCL患者中描述现实世界的结果.
- 为了确定与这种患者群体中较差的结果相关的因素.
主要方法:
- 从2010年1月至2022年3月期间诊断出DLBCL的4226名患者的电子健康记录的回顾性分析.
- 纳入标准要求R/R DLBCL接受至少一种先前疗法 (LOT),包括含有抗CD20的治疗方案.
- 分析了符合这些标准的573名患者队列.
主要成果:
- 这项研究包括573名R/R DLBCL患者,其中31.2%接受过≥2次之前的LOT.
- 总体响应率 (ORR) 为52%,完整响应率 (CR) 为23%.
- 无进展生存时间 (PFS) 中位数为3.0个月,总生存时间 (OS) 中位数为12.9个月. 患有更多先前LOT,原发性折射性或先前暴露于CAR T细胞治疗的患者经历了更糟糕的结果.
结论:
- 对于R/R DLBCL的标准治疗,包括化疗和抗CD20药物,产生低于最佳的结果,特别是在具有挑战性的治疗病例中.
- 对于R/R DLBCL患者的创新性和有效疗法的需求至关重要,特别是那些患有耐火性疾病或多种先前治疗线路的患者.
更多相关视频
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.4K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
01:21Cancer Survival Analysis
348
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
348
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K